Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma-Reference-Cited by-同舟云学术

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma

Published:2014-07-08 Issue:9 Volume:63 Page:789-796
ISSN:1023-3830
Container-title:Inflammation Research
language:en
Short-container-title:Inflamm. Res.

Author:

Ishizuka Tamotsu,Hisada Takeshi,Hatori Motoaki,Koike Akio,Hanabuchi Kikuo,Matsuzaki Shinichi,Kamide Yosuke,Utsugi Mitsuyoshi,Aoki Haruka,Yoshino Reiko,Yanagitani Noriko,Koga Yasuhiko,Ono Akihiro,Kaira Kyoichi,Sunaga Noriaki,Dobashi Kunio,Tsuburai Takahiro,Akiyama Kazuo,Yamada Masanobu,Suzuki Kazuhiro,Mori Masatomo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology

Link

http://link.springer.com/content/pdf/10.1007/s00011-014-0753-1.pdf

Reference46 articles.

1. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–41.

2. Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17:1–342.

3. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98.

4. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84.

5. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening asymptomatic school children for early asthma by determining airway narrowing through peak expiratory flow rate measurement;Journal of Education and Health Promotion;2020